Clinical Trial Update: A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent [Phase 2]

View source ↗

Summary

Phase 2 randomized, double-blind trial evaluating the safety and performance of the NIRx Paclitaxel-Coated Conformer Coronary Stent in coronary artery disease; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• NIRx Paclitaxel-Coated Conformer Coronary Stent (paclitaxel-coated conformer coronary stent)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Coronary Artery Disease | Phase 2 | Status: COMPLETED